{"id":61954,"date":"2026-03-31T15:10:24","date_gmt":"2026-03-31T07:10:24","guid":{"rendered":"https:\/\/flcube.com\/?p=61954"},"modified":"2026-03-31T15:10:25","modified_gmt":"2026-03-31T07:10:25","slug":"shaanxi-micot-files-hkse-listing-application-to-advance-bifunctional-peptide-drug-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61954","title":{"rendered":"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline"},"content":{"rendered":"\n<p><strong>Shaanxi Micot Pharmaceutical Technology Co., Ltd.<\/strong>, a Xi&#8217;an-based developer of bifunctional and multi-functional peptide therapeutics, has filed its prospectus with the <strong>Hong Kong Stock Exchange (HKSE)<\/strong> for a <strong>Main Board listing<\/strong>. The biotechnology company focuses on discovering, developing, and commercializing <strong>bi-specific\/multi-specific peptide drugs<\/strong> targeting metabolic diseases and cardiovascular\/cerebrovascular disorders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-pipeline-overview\">Company Profile &amp; Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Development Stage<\/th><th>Target Indications<\/th><\/tr><\/thead><tbody><tr><td><strong>MT1013 (Core Product)<\/strong><\/td><td>Phase III<\/td><td>Secondary hyperparathyroidism (SHPT), CKD-MBD with osteoporosis, non-dialysis SHPT<\/td><\/tr><tr><td><strong>Additional Pipeline Candidates<\/strong><\/td><td>6 candidates<\/td><td>Metabolic diseases, cardiovascular and cerebrovascular disorders<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Proprietary<\/td><td>Bi-specific\/multi-specific peptide drug discovery<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Global<\/td><td>China-based development with international expansion potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-product-mt1013-clinical-profile\">Core Product: MT1013 Clinical Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Self-developed <strong>bi-specific receptor agonist peptide<\/strong> targeting both <strong>CaSR (Calcium-Sensing Receptor)<\/strong> and <strong>OGP (Osteogenic Growth Peptide)<\/strong> receptors<\/li>\n\n\n\n<li><strong>Primary Indication:<\/strong> <strong>Secondary hyperparathyroidism (SHPT)<\/strong> \u2013 a condition affecting millions of patients with chronic kidney disease<\/li>\n\n\n\n<li><strong>Expansion Opportunities:<\/strong><\/li>\n\n\n\n<li>Chronic kidney disease-mineral and bone disorder (CKD-MBD) with osteoporosis<\/li>\n\n\n\n<li>Non-dialysis secondary hyperparathyroidism<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Advanced Phase III trials, positioning for near-term commercialization<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-market-positioning\">Strategic Market Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitive Advantage<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>Novel Mechanism<\/strong><\/td><td>Dual-targeting approach addresses complex pathophysiology of mineral and bone disorders<\/td><\/tr><tr><td><strong>Unmet Medical Need<\/strong><\/td><td>SHPT affects approximately 40-60% of dialysis patients globally with limited treatment options<\/td><\/tr><tr><td><strong>Platform Scalability<\/strong><\/td><td>Proprietary peptide technology enables rapid development of additional multi-specific candidates<\/td><\/tr><tr><td><strong>Market Access Strategy<\/strong><\/td><td>HKSE listing provides capital for global clinical development and commercial infrastructure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-strategic-implications\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Markets Strategy:<\/strong> HKSE Main Board listing positions Micot alongside other leading Chinese biotech companies<\/li>\n\n\n\n<li><strong>Funding Requirements:<\/strong> Proceeds expected to support Phase III completion, regulatory submissions, and commercial launch preparation<\/li>\n\n\n\n<li><strong>Global Expansion Potential:<\/strong> Dual CaSR\/OGP targeting mechanism offers patent protection and differentiation in competitive SHPT market<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Six additional candidates provide optionality across metabolic and cardiovascular therapeutic areas<\/li>\n<\/ul>\n\n\n\n<p>The company&#8217;s focus on multi-specific peptide drugs represents an emerging frontier in precision medicine, combining the specificity of biologics with the developability advantages of peptides. MT1013&#8217;s advanced development stage provides near-term visibility while the broader pipeline offers long-term growth potential.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook\">Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SHPT Market Size:<\/strong> Estimated at USD 2-3 billion globally with significant growth potential in aging populations<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Phase III data expected to support filings in China, US, and EU markets<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Differentiated from calcimimetics and vitamin D analogs through dual-mechanism approach<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Likely partnership opportunities with established nephrology-focused pharmaceutical companies<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Micot&#8217;s clinical development, regulatory strategy, and capital markets activities. Actual results may differ due to clinical trial outcomes, regulatory decisions, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/sehk26033100613_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26033100613_c.\"><\/object><a id=\"wp-block-file--media-e18ba21e-799b-475e-afaa-ab16152c41ac\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/sehk26033100613_c.pdf\">sehk26033100613_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/sehk26033100613_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e18ba21e-799b-475e-afaa-ab16152c41ac\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi&#8217;an-based developer of bifunctional and multi-functional peptide therapeutics,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61959,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,4205],"class_list":["post-61954","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-micot"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi&#039;an-based developer of bifunctional and multi-functional peptide therapeutics, has filed its prospectus with the Hong Kong Stock Exchange (HKSE) for a Main Board listing. The biotechnology company focuses on discovering, developing, and commercializing bi-specific\/multi-specific peptide drugs targeting metabolic diseases and cardiovascular\/cerebrovascular disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61954\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline\" \/>\n<meta property=\"og:description\" content=\"Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi&#039;an-based developer of bifunctional and multi-functional peptide therapeutics, has filed its prospectus with the Hong Kong Stock Exchange (HKSE) for a Main Board listing. The biotechnology company focuses on discovering, developing, and commercializing bi-specific\/multi-specific peptide drugs targeting metabolic diseases and cardiovascular\/cerebrovascular disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61954\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T07:10:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T07:10:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline\",\"datePublished\":\"2026-03-31T07:10:24+00:00\",\"dateModified\":\"2026-03-31T07:10:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954\"},\"wordCount\":435,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3102.webp\",\"keywords\":[\"IPO\",\"Micot Pharmaceutical Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61954#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61954\",\"name\":\"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3102.webp\",\"datePublished\":\"2026-03-31T07:10:24+00:00\",\"dateModified\":\"2026-03-31T07:10:25+00:00\",\"description\":\"Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi'an-based developer of bifunctional and multi-functional peptide therapeutics, has filed its prospectus with the Hong Kong Stock Exchange (HKSE) for a Main Board listing. The biotechnology company focuses on discovering, developing, and commercializing bi-specific\\\/multi-specific peptide drugs targeting metabolic diseases and cardiovascular\\\/cerebrovascular disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61954\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61954#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi'an-based developer of bifunctional and multi-functional peptide therapeutics, has filed its prospectus with the Hong Kong Stock Exchange (HKSE) for a Main Board listing. The biotechnology company focuses on discovering, developing, and commercializing bi-specific\/multi-specific peptide drugs targeting metabolic diseases and cardiovascular\/cerebrovascular disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61954","og_locale":"en_US","og_type":"article","og_title":"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline","og_description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi'an-based developer of bifunctional and multi-functional peptide therapeutics, has filed its prospectus with the Hong Kong Stock Exchange (HKSE) for a Main Board listing. The biotechnology company focuses on discovering, developing, and commercializing bi-specific\/multi-specific peptide drugs targeting metabolic diseases and cardiovascular\/cerebrovascular disorders.","og_url":"https:\/\/flcube.com\/?p=61954","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T07:10:24+00:00","article_modified_time":"2026-03-31T07:10:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61954#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61954"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline","datePublished":"2026-03-31T07:10:24+00:00","dateModified":"2026-03-31T07:10:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61954"},"wordCount":435,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61954#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102.webp","keywords":["IPO","Micot Pharmaceutical Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61954#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61954","url":"https:\/\/flcube.com\/?p=61954","name":"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61954#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61954#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102.webp","datePublished":"2026-03-31T07:10:24+00:00","dateModified":"2026-03-31T07:10:25+00:00","description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi'an-based developer of bifunctional and multi-functional peptide therapeutics, has filed its prospectus with the Hong Kong Stock Exchange (HKSE) for a Main Board listing. The biotechnology company focuses on discovering, developing, and commercializing bi-specific\/multi-specific peptide drugs targeting metabolic diseases and cardiovascular\/cerebrovascular disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61954#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61954"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61954#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102.webp","width":1080,"height":608,"caption":"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61954#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61954"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61954\/revisions"}],"predecessor-version":[{"id":61960,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61954\/revisions\/61960"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61959"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}